Current Report Filing (8-k)
01 June 2016 - 3:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date
of Earliest Event Reported):
May 25, 2016
SCRIPSAMERICA, INC.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
000-54550
|
26-2598594
|
(State of Incorporation)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
1094
Main Avenue, Suite A, Clifton, NJ
|
07011
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(800) 957-7622
(Former name or former address,
if changed since last report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events
Financing Activities
On May 3, 2016, in its Form 8-K filing, Registrant discussed certain
inter-related financing matters resulting from certain actions being taken by Express Scripts, Inc. (“ESI”). In summary,
due to an investigation related to prescriptions written by a telemarketing doctor and filled by Registrant’s subsidiary,
Main Avenue Pharmacy, Inc. (“Main Avenue”), Express Scripts, Inc., as the representative of the various health insurance
carriers who paid for such prescriptions, was withholding approximately $3.55 million of funds owing to Main Avenue and indicated
that it might demand reimbursement by Main Avenue. The actions being taken by ESI caused a technical default under the financing
documents covering borrowings against Main Avenue’s accounts receivable, of which Main Avenue received notice from the lender
on April 26, 2016.
Main Avenue received and filled prescriptions written by the doctor
from the fourth quarter of 2014 (9/16/2014) through the first quarter of 2016 (1/30/2016), being most of the period that Main Avenue
has been a subsidiary of the Registrant. In its notification on May 25, 2016, ESI has declared that the doctor did not have the
requisite relationship with the patients for whom he wrote the prescriptions and that, accordingly, the prescriptions were not
valid. In conclusion, ESI has indicated that it will not release any of the $3.55 million being held and, in addition, has demanded
repayment of $12,155,159.97 almost all of which is due to the claimed “invalid Patient/Prescriber Relationship”. Finally,
ESI has terminated Main Avenue’s Network Provider Agreement/Status.
Registrant’s Management is considering its options and potential
responses.
Since receipt of the notice of default, on April 26, 2016, from
the accounts receivable lender, Main Avenue has discontinued all new borrowings, has been seeking to develop a workout plan with
the lender, and has implemented a repayment program which is already proceeding pending a mutually acceptable workout plan. Main
Avenue continues with its business plan.
Of the $12,155,159.97, an estimated amount of $1 million came to
Main Avenue from Medi Biotech and is being counterclaimed in the pending lawsuit.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ScripsAmerica, Inc
|
|
|
Date: May 31, 2016
|
By:
/s/ Brian Ettinger
|
|
Brian Ettinger
|
|
Chief Executive Officer
|
ScripsAmerica (CE) (USOTC:SCRCQ)
Historical Stock Chart
From Jan 2025 to Feb 2025
ScripsAmerica (CE) (USOTC:SCRCQ)
Historical Stock Chart
From Feb 2024 to Feb 2025
Real-Time news about ScripsAmerica Inc (CE) (OTCMarkets): 0 recent articles
More Scripsamerica, Inc. News Articles